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Abstract 
 
PURPOSE: Cancer-related fatigue in adults has been the subject of considerable 
recent research , confirming its importance as a common and debilitating symptom, 
and establishing a number of evidence-based interventions. There has, however, 
been limited focus on the fatigue suffered by teenagers and young adults with 
cancer, a group recognized as having unique experiences and developmental 
needs. We have undertaken a systematic review of the literature, to provide a 
comprehensive overview of studies evaluating fatigue in this younger patient group, 
in order to guide clinical practice and future research. 
 
METHOD: We searched MEDLINE, EMBASE, PsycINFO, and CINAHL databases 
for literature containing data relating to any aspect of fatigue in patients aged 13–24 
at cancer diagnosis or treatment. 
 
RESULTS: Sixty articles were identified, of which five described interventional 
clinical trials. Cancer-related fatigue was consistently one of the most prevalent, 
severe, and distressing symptoms, and it persisted long-term in survivors. It was 
associated with a number of factors, including poor sleep, depression, and 
chemotherapy. There was little evidence for the effectiveness of any intervention, 
although exercise appears to be the most promising. Importantly, fatigue was itself a 
significant barrier to physical and social activities. 
 
CONCLUSION: Cancer-related fatigue is a major and disabling problem in young 
cancer patients. Effective management strategies are needed to avoid compounding 
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the dependence and social isolation of this vulnerable patient group. Future research 
should focus on providing evidence for the effectiveness of interventions, of which 
activity promotion and management of concurrent symptoms are the most promising. 
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Cancer is the leading cause of disease-related death in teenagers and young 
adults (TYAs) in the United States and Europe.1,2 Each year, more than 11,000 TYA 
patients in the United States and over 2,000 in the United Kingdom are diagnosed 
with cancer, and incidence rates are rising.2,3 It is increasingly recognized that such 
patients have experiences and needs that differ significantly from those of children 
and adults.4 As well as having to negotiate the physical, cognitive, emotional, and 
behavioral changes that occur in adolescence, young people can suffer from a 
different cancer profile, longer periods of cancer treatment, a worse prognosis, and a 
particularly devastating sense of despair and isolation.3,5,6 There has been an 
international drive to develop age-appropriate specialist care and to generate an 
evidence base addressing the specific needs of this patient group.4,7 
Cancer-related fatigue is a “persistent, subjective sense of tiredness related to 
cancer or cancer treatment that interferes with usual functioning.”8 It is a multi-
dimensional symptom with physical, affective, and cognitive components. The range 
of perceptions may include a feeling of weakness and inability to perform tasks, 
decreased motivation and low mood, and difficulty in thinking clearly.9 It differs from 
fatigue felt by healthy individuals in that it is of greater magnitude, disproportionate to 
the level of exertion, and incompletely relieved by rest. 
Fatigue appears to be both the most common and the most distressing 
symptom experienced by adult patients with cancer.10,11 Many surveys suggest a 
prevalence of over 75%, with rates increasing in conjunction with oncological 
treatment.12,13 Adult patients report that fatigue is the symptom which has the 
greatest negative impact on their quality of life.11 
Despite the size of the problem, cancer-related fatigue has traditionally been 
neglected both in clinical and research terms, with healthcare staff and patients 
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tending to consider it an unavoidable consequence of cancer and its treatment.10,14 
However, over the last two decades, a substantial evidence base has been 
developing in the adult literature. Systematic reviews of research in older adults has 
shown that—apart from treating reversible underlying causes—the most promising 
approaches are exercise15 and psychosocial interventions such as education.16 
Recognition of the particular importance of cancer-related fatigue in younger 
cancer patients has only emerged over the last 5-10 years. Lack of energy has been 
shown to be the most common symptom in children with cancer, with children 
placing emphasis on a sense of physical weakness, associating fatigue with 
disruption of sleep.17  TYA cancer patients also appear to suffer from significant 
fatigue,18-20 unsurprising given that even healthy teenagers and young adults have a 
propensity to experience fatigue. The developmental need for longer sleep during 
this important phase of brain maturation is hindered by circadian rhythm shifts and a 
tendency to develop unhelpful sleep habits.21,22 TYAs perceive fatigue in both 
cognitive and physical terms.5 Fatigue is believed to have a particularly negative 
impact on quality of life in this group, as it hinders many of the key developmental 
needs of this age, such as autonomy and the formation of close peer relationships.23 
Many TYA cancer patients remain or return to being dependent on their parents at a 
time when they would have been expecting to achieve independence. It is well-
recognized clinically that the parents of fatigued TYAs bear a considerable burden. 
One previous review of fatigue in teenagers in cancer was published a 
decade ago;20 Erikson found there was minimal research focusing on fatigue in this 
age range. Given the number of articles published since this review, it was decided 
to systematically appraise the current evidence base with a focus on the TYA age 
group. The review was designed to be broad to provide a comprehensive overview 
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of studies investigating any aspect of cancer-related fatigue in patients diagnosed or 
treated for cancer while aged 13-24. The research questions were: 
1. What is the prevalence and severity of cancer-related fatigue in TYA 
patients during and after treatment? 
2. What is the impact of fatigue on TYA cancer patients? 
3. What is the experience of parents of fatigued TYA cancer patients? 
4. What are the correlates of cancer-related fatigue in this patient group? 
5. How effective are interventions to manage fatigue in TYA patients? 
 
Methods 
Literature search strategy 
The literature was searched within MEDLINE, EMBASE, PsycINFO, and 
CINAHL databases for January 1981 through October 2013. Preliminary searches 
had suggested that there was no literature of relevance published prior to 1981.The 
search strategy is detailed in Table 1. Reference and citation searches were also 
undertaken, with manual searching of all issues of a key journal—the Journal of 
Adolescent and Young Adult Oncology (volume 1 issue 1 to volume 2 issue 4)—as 
well as the proceedings of the 2012 Teenage Cancer Trust International Conference. 
Related systematic reviews were searched, including reviews evaluating symptoms 
experienced by teenagers with cancer,24 fatigue in lymphoma patients,25 and 
interventions for fatigue in children and adults.26,27Experts in teenage and young 
adult cancer-related fatigue were also contacted. 
 
Selection criteria 
The key inclusion criteria were that all study participants had malignant 
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disease, and that either the majority were aged 13–24 years-old at the time of cancer 
diagnosis or treatment or the results for this age subgroup were presented 
separately. Included studies could investigate any aspect of cancer-related fatigue, 
use any outcome measure, and employ quantitative or qualitative methods. 
Exclusion criteria included non-English language publication, absence of original 
empirical data, phase I/II clinical trials, trials involving fewer than 10 patients, case 
reports, and retrospective case note reviews. Studies of TYA-aged survivors of 
pediatric cancer were not included. 
 
Quality assessment and data analysis 
Gough’s Weight of Evidence Framework28 was employed to assess article 
quality, relevance, and bias, and to generate an overall judgment about contribution. 
This framework includes analysis of ‘fitness for purpose’ and relevance to the 
research question, providing a more applied synthesis of evidence than simply 
assessing the generic quality of each article. Four scores of ‘low’, ‘medium’ or ‘high’ 
are given for each of the following:  
 Weight of Evidence A: The integrity of the evidence in its own terms 
 Weight of Evidence B: The appropriateness of method for answering 
the review questions 
 Weight of Evidence C: The appropriateness of the focus or relevance 
for answering the review questions 
 Weight of Evidence D: The overall rating generated by combining the 
Weight of Evidence A, B, and C scores  
All articles, irrespective of relevance and quality, were included, but those rated 
‘medium’ and ‘high’ were given greater weight in the analysis. 
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The searches produced 2388 unique titles that were initially screened by one 
researcher (AS). After 566 abstracts were reviewed by two researchers (AS and 
SG), 343 full articles were read by one researcher (AS), who excluded most of them 
on the basis of the participants’ ages. Two researchers (AS and SB) read the 
remaining articles, with disagreements resolved by discussion. The final number of 
included articles was 60 (Fig. 1). A narrative synthesis was undertaken in relation to 
each of the research questions. 
 
Results 
Description of articles 
Thirty-seven of the 60 included articles were from the United States or 
Canada, eight were from Norway or Sweden, and three were from the United 
Kingdom. All were published between 1992 and 2013. The 60 articles encompassed 
a total of 52 separate studies, as four pairs of articles23,29-35 and two groups of three 
articles36-41 were publications describing different aspects of the same study’s data 
set. It was decided to handle these as different studies, because of their distinct 
areas of focus. Therefore, for the purposes of this review, the 60 articles were 
viewed as 60 separate studies. 
Thirty-six studies were cross-sectional and observational. Of the 24 
prospective longitudinal studies, five were interventional clinical trials. Most studies 
involved only quantitative methods, though seven were qualitative and eight 
employed a mixed-methods design. Most were rated as medium or poor on Gough’s 
Weight of Evidence Framework. Although 13 were of high quality on Weight of 
Evidence A (integrity of the evidence in its own terms),17,30,40,42-51 only three were 
judged to be of overall high quality by Weight of Evidence D.17,30,47 
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All participants (aside from those in some of the control groups) had a cancer 
diagnosis. Five studies only recruited patients with lymphoma and/or 
leukemia,31,32,45,52,53 and one had only patients with extremity bone tumors.54 All of 
the remaining studies investigated more than one cancer type. The majority of 
participants were in the 13–24 age range in 46 studies; subgroup data for this age 
range was presented separately in the remaining 14 papers. The number of patients 
within each study ranged from 855 to 199,56 and the median or mean time since 
diagnosis ranged from 2 months57 to 20 years.32 
Fatigue was the study’s focus and the first outcome measure described in the 
results for only 18 studies;5,18,19,23,30-32,35,36,42,46,47,50,54,58-61 two of these involved 
validating symptom measures46,59 and none were interventional. Across the 60 
included studies, the most commonly used fatigue outcome measures were the 
Fatigue Scale-Adolescent (FS-A),59 the Multidimensional Fatigue Scale (MFS),62 and 
the Memorial Symptom Assessment Scale (MSAS 10-18),63 used in 14,12 and eight 
studies, respectively.  Eleven studies used a range of other validated fatigue 
measures, including the Chalder Fatigue Questionnaire, Piper Fatigue Scale and the 
Functional Assessment in Chronic Illness Therapy fatigue scale. Eight studies used 
unvalidated measures, and the remaining seven studies were entirely qualitative in 
design. Table 2 provides further detail on the more commonly used measures. 
 
Fatigue prevalence 
Twenty-four studies investigated the prevalence of TYA cancer-related fatigue 
(Table 3). Fatigue was measured during treatment in 14 studies, after treatment in 
five studies, and in a mixed population of patients both during and after treatment in 
five studies. A ‘fatigue case’ was most commonly defined as fatigue being scored as 
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‘present’ using the MSAS, a score of anything other than ‘no fatigue’ on a 5-point 
Likert scale, or a dichotomized score of ≥4 on the Chalder Fatigue Scale.64 
The heterogeneity of study populations, outcome measures, and definitions of 
‘fatigue case’ hindered comparison of prevalence data between studies and 
prevented meta-analysis. Fatigue prevalence ranged from 7%47 to 100%65 during 
treatment, 9%50 to 67%66 after treatment, and between 31%56 and 100%67 in the 
mixed populations. As detailed in Table 3, the prevalence of fatigue and other 
symptoms were compared on 20 occasions in 10 studies; it was the most prevalent 
symptom on 11 occasions17,33,34,65,68-71 and the second-most prevalent on six 
occasions.17,71-73 
Two studies—both with survivor populations—included a control group; both 
used non-contemporaneous controls. Aksnes et al. found a fatigue prevalence of 
14% in extremity bone tumor survivors, which was not significantly different from that 
of age- and gender-matched cases from healthy population surveys (p = 0.30).54 In 
contrast, Hamre et al. reported a fatigue prevalence of 34% in survivors of Hodgkin 
lymphoma, compared to 8% in an unmatched healthy control population (p < 
0.001).32 
 
Fatigue severity 
The severity of fatigue was measured in 32 instances: 20 studies during 
treatment, five studies after treatment, six studies with a mixed cohort of patients 
both during and after treatment, and one study that provided data on two separate 
patient cohorts during and after treatment, respectively.  Seven studies reported 
relative severity of fatigue in comparison to other symptoms; fatigue was most 
severe in four studies,34,52,68,69 second-70 and third-most72 severe in one study each, 
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and fourth-most severe in two studies.40,67 Fourteen different outcome measures 
were used across these 30 studies. The most commonly used outcome measures 
were the FS-A, MFS, and MSAS, in nine, eight, and four studies each, respectively. 
Comparison and synthesis of severity scores was again not possible due to 
heterogeneity of study populations, methods of reporting the data (for example, 
absolute score or percentage with score above a defined value), or measures used. 
Three studies incorporated a control group, all of which compared fatigue 
severity in patients during treatment to that in survivors (Table 4). Controls ranged 
from contemporaneous recruits to unmatched reference data. All three studies 
showed significantly greater fatigue severity in the cancer groups compared to the 
controls. 
Eight studies compared fatigue severity between younger children and 
teenagers treated for cancer, of which five measured fatigue with both the Fatigue 
Scale-Adolescent (FS-A) and the Fatigue Scale-Child (FS-C).37,53,60,74,75 The FS-A 
and FS-C76 each use 14 age-appropriate questions and are validated for 13-18 and 
7-12 year olds, respectively. Fatigue was reported as being more severe in 
adolescents than in younger children in all but one of the eight studies.53  
Many of the studies that used the FS-A outcome also measured parent 
reports of fatigue,37,38,47,49,59,60,74,75,77 but patient and parent scores are not directly 
comparable. One study did directly compare the fatigue scores of TYA patients with 
proxy scores from their caregivers, and found that their caregivers tended to 
overestimate their fatigue severity.30 
Fatigue severity was assessed over time in 11 longitudinal studies; all 
involved participants currently receiving chemotherapy.23,35,37,57,60,68,71,75,77-79 In 
general, fatigue scores were worse in the two weeks after receiving chemotherapy 
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and then improved until the next cycle. No longitudinal studies investigated fatigue 
severity over the longer period from treatment into survivorship. One small cross-
sectional, observational study of three groups of adolescents during treatment (n = 
8), 1–2 years after treatment (n = 6), and five or more years after treatment (n = 8) 
found that fatigue scores were highest during treatment, lowest during early 
remission, and higher again during late remission.18 
 
Impact of fatigue 
Twenty-two studies reported the impact of fatigue on patients.17-19,23,33,34,37,39-
43,48,55,68,72,73,80-84 Distress caused by fatigue was the most commonly described 
impact, reported in 11 studies. The MSAS, a scale that allows comparison of the 
level of distress caused by each symptom, was used in six of these 
studies.17,33,34,68,72,73 When symptoms were ranked in order of distress, fatigue was in 
the top half with only one exception.17 One study reported that distress was 
correlated with the frequency and severity of fatigue.34 The remaining five studies 
used diverse measures of distress,40,43,55,82,83 and fatigue was one of the top four 
most distressing conditions in four of these studies.40,43,82,83  
The second-most frequently described impact of fatigue was that it was a 
barrier to physical activity or exercise, which was reported in six studies.18,23,42,80,81,84 
Fatigue was the first-80 and second-most84 significant barrier in one study each. 
Being unable to take part in exercise led to frustration and loss of confidence, with 
parents becoming ‘overprotective’ and preventing their adolescents from taking part 
in activities that demanded energy.42 Four studies reported fatigue as a barrier to 
other social activities,18,23,42,48 including returning to school.48 A negative impact on 
affective state, mood, or anxiety was described in three studies.19,23,37 
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Experience of parents 
Although 10 studies collected parent proxy reports of fatigue 
severity,30,37,38,47,49,59,60,74,75,77 none investigated the experiences of parents of 
adolescent teenagers or young adults with cancer-related fatigue. Parent proxy 
reports of fatigue severity correlated more closely with those of their children for 
parents of cancer patients than for parents of healthy controls, which was attributed 
to the cancer patients’ parents being ‘physically closer’ and ‘more attuned to the 
needs’ of their children.30,59,61 However, cancer patients’ parents appeared to be less 
adept than the patients themselves at perceiving changes in fatigue over time.60,77 
One study collected staff proxy reports of patient fatigue as well as parent proxy 
reports,59 and found that staff reports correlated less tightly than parent reports with 
patients’ self-reported fatigue. 
 
Fatigue correlates 
Factors correlating with the presence or severity of fatigue were reported in 27 
studies, including five of the six scoring highest on the Gough’s Weight of Evidence 
Framework.30,38,47,49,51 
Eleven studies highlighted an association between fatigue and physical 
symptoms, including poor sleep,35,37,57,61,74,75 being part of a symptom cluster,33,70,73 
and nausea.29,61 Almost all participants in the three studies that examined symptom 
clusters were receiving chemotherapy;33,70,73 although there was no consistency in 
the specific symptoms found to cluster with fatigue, the symptoms tended to be 
chemotherapy-related. While receiving chemotherapy23,36,44,47,60,66 or 
dexamethasone45 both correlated with increasing fatigue, the evidence for a 
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correlation between fatigue and hospital admission47,60,72 or anemia46,60 was 
conflicting. Even though patients associated fatigue with ‘doing too many things’ or 
‘being too active,’5,23 there was a correlation between improved performance status 
and lower fatigue scores.46,78 
Depression or low mood correlated with fatigue in five studies;30,38,59,61,85 
negative affect,29 global distress,72 anxiety,33,73 and non-specific psychological 
conditions44,72 were identified as correlates in a further five publications. Consistent 
with the link with physical and psychological symptoms, a high correlation with poor 
quality of life or satisfaction with life was reported in four studies.23,30,66,85  
Although some of these correlations are intuitively likely to represent causal 
relationships—such as the relationship between fatigue and poor sleep quality—no 
studies addressed causality. However, one longitudinal study that observed a 
predictable fluctuation in fatigue during chemotherapy regimens of varying 
frequency23 and a study involving planned periods on and off dexamethasone45 both 
suggested causal relationships with fatigue. 
 
Interventions to manage fatigue 
Table 5 details the five interventional trials for TYA cancer patients in which 
fatigue was used as an outcome measure.43,74,79,86,87 Fatigue was not stated to be 
the primary outcome measure in any of the five. Three studies were 
uncontrolled79,86,87 and three were feasibility studies.74,79,87 Four involved evaluation 
of a structured activity intervention, and one investigated a self-care coping 
intervention. All of the interventions were standardized with a degree of 
individualization in accordance with each patient’s exercise capacity. Two 
uncontrolled trials found a statistically significant benefit from their interventions,79,86 
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which involved intensive structured exercise in a gymnasium at weekly intervals for 
more than two months. The remaining two physical activity intervention studies 
involved bringing portable gym equipment to the patient’s hospital room and did not 
find any significant effect.74,87 The self-care coping intervention was also 
ineffective.43 
 
Discussion 
This review provides evidence that fatigue is one of the most prevalent and 
severe symptoms experienced by teenagers and young adults suffering from cancer, 
occurring in the majority of patients and particularly prevalent during cancer 
treatment. This finding is consistent with evidence in adults with cancer, for whom 
fatigue is now accepted as the most prevalent symptom.11 
There were no studies comparing TYA patients’ fatigue with that of older 
adults with cancer. However, a number of publications compared fatigue in TYA 
patients to that in young children, with fatigue being more severe in the TYA 
population. This is consistent with the developmental sleep changes of adolescence. 
Healthy teenagers tend to develop fatigue and daytime sleepiness related to 
inadequate sleep.21 At this age, longer sleep is needed, yet shifts in circadian 
rhythms result in later bed times; the amount of time spent sleeping is further limited 
by unhelpful sleep habits, such as caffeine consumption and social engagements.21 
Controlled studies have shown that fatigue in teenaged and young adult cancer 
patients is even higher than that in healthy controls.30,32,51,54 The dual risk factors for 
fatigue development—having cancer and being within or soon after the teenaged 
years—appear to combine to create a particularly significant problem in this 
vulnerable patient group. 
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Cancer-related fatigue is not only present during or soon after treatment: 
several studies of TYA cancer survivors showed long-term continuation of fatigue 
many years after cancer diagnosis and treatment.32,52,54 Given that TYA cancer 
patients have an approximately 80% five-year survival rate,6 this means that large 
numbers of young people are contending with ongoing morbidity while attempting to 
rebuild their lives after a cancer diagnosis. 
Not only is fatigue prevalent, severe, and persistent, there is consistent 
evidence that fatigue causes significant distress, with a negative impact on quality of 
life. Fatigue may be a particularly distressing symptom in teenagers and young 
adults because of its impact on functioning at an age when independence and social 
interactions are high priorities. The inherent social isolation resulting from the 
diagnosis of a serious disease at a young age that can require years of burdensome 
treatment is further compounded by the presence of fatigue. The level of distress 
may also reflect the developmental stage of teenagers and young adults, who are 
more able than children to understand the significance of their symptoms and 
underlying cancer, yet may be less able to control and rationalize their emotions than 
older adults. 
Despite the increasingly strong and consistent evidence base confirming the 
magnitude of the problem, there are no published studies evaluating interventions 
whose primary aim is to treat or prevent fatigue. The few interventional studies to 
date are mostly uncontrolled or feasibility studies investigating physical activity. 
Exercise is recognized as an effective treatment in adults with cancer-related fatigue. 
The presence of fatigue hinders activity which then leads to deconditioning (or loss 
of ‘fitness’). This in turn worsens the fatigue, so leading to a vicious circle that 
perpetuates the symptom. Exercise or activity is believed to work, as least in part, by 
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preventing deconditioning and the development of this vicious cycle. Although two of 
the four physical activity interventional studies did report significant findings, both 
were uncontrolled. Given the well-established placebo effect that occurs with 
subjective symptoms such as fatigue,88 the strength of existing evidence for 
intervention effectiveness in the TYA age group is, as yet, poor. 
In the context of physical activity being the only intervention for fatigue with 
any—albeit limited—supporting evidence in the TYA literature, a significant finding of 
this review is that fatigue itself is a key barrier to activity. There is mounting evidence 
that resting is perceived by patients, parents, and healthcare professionals as the 
best approach to managing fatigue. Studies have found that young patients feel that 
‘being too active’ or ‘doing too many things’ may worsen fatigue;5,23 that parents 
encourage rest;42 and that in a mixed child and teenage population, healthcare 
professionals’ most commonly recommended treatment for fatigue was rest and 
relaxation.89 
There is evidence that activity levels tend to decline during the teenaged 
years due to conflicting priorities, fear of injury and a sense of embarrassment.90 It is 
conceivable that TYA cancer patients may be particularly prone to such decline in 
activity; there may be perceived increased vulnerability to injury, and disease- or 
treatment-related bodily changes that could potentially cause self-consciousness.90 
Cancer-related fatigue, in combination with these normal teenage inhibitions, can 
therefore present a formidable barrier to activity, paradoxically the very intervention 
that appears to have the greatest potential to improve their fatigue. Furthermore, at 
this formative age, life-long habits are developed. Maladaptive behaviors such as 
inactivity are therefore even more likely to persist, perpetuating fatigue and its 
associated disability and adverse psychosocial sequelae long-term. 
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Strengths and limitations 
The main strength of this review is its breadth: studies were eligible if they 
investigated any aspect of cancer-related fatigue in TYA-aged patients, and even 
those with only a subgroup of patients aged 13–24 were included. The database 
search strategy was effective, with five articles found from other searches. The 
included studies, however, were heterogeneous and of relatively low quality, limiting 
the strength of the findings. Although experts in the field were contacted, literature 
not formally published in the form of journal articles (so-called ‘grey’ literature) may 
have been missed. Exclusion of articles not in English may also have led to the 
omission of relevant articles. 
 
Implications for clinical practice 
Clinicians should be aware of the prevalence and severity of fatigue in TYA 
cancer patients, as well as the significant distress it causes. It is possible that a 
degree of therapeutic nihilism has developed due the lack of clearly effective 
pharmacological interventions for fatigue.91  Simply inquiring about the presence of 
fatigue in each clinical encounter may in itself be helpful, as this can openly 
acknowledge the problem and provide the possibility for peer and professional 
support. 
Although the evidence base for exercise interventions is very limited, it is clear 
that encouragement of physical activity is likely to be helpful. In adults, it is well 
established that exercise improves cancer-related fatigue.15,92 The wider benefits of 
keeping active during and after cancer treatment include increased well-being, 
functioning, and quality of life, as well as reduced cancer recurrence and mortality.93-
20 
 
96 Clinicians, potentially lacking the time and knowledge to counsel TYA patients 
about physical activity, should develop the skills to educate and address any 
misconceptions of TYA patients and their parents about the benefits of activity. This 
should include confirming its potential to ameliorate rather than—as intuitively 
expected—worsen fatigue. 
The correlation between fatigue and concurrent symptoms, such as poor 
sleep, is consistent with the evidence in adults that the management of sleep 
disorders97 and other symptoms98 can improve cancer-related fatigue. Rigorous 
control of concurrent symptoms, including education about sleep needs and habits in 
adolescence, may have a positive impact on fatigue. 
 
Implications for future research 
This review has revealed many gaps in the literature. Further prevalence 
studies are needed with concurrent controls, using a longitudinal design to evaluate 
changes in fatigue and fatigue-related distress within a cohort from treatment into 
long-term survivorship. It would be valuable to compare fatigue severity and 
associated distress in TYAs and older adults. Future studies could usefully attempt 
to establish the directionality of relationships between fatigue and other factors 
Determination of factors that cause, rather than are simply associated with, fatigue 
could helpfully guide fatigue management. Evidence for this review came from only 
five countries; further global research into TYA cancer-related fatigue is needed. 
Use of dexamethasone in the TYA population appears to worsen fatigue by 
reducing sleep efficiency and increasing night-time wakenings.45 Conversely, in 
adults, this drug may improve fatigue.99 This conflicting evidence may indicate a 
genuine difference in the reaction to steroids of adolescents compared to older 
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adults, and is worthy of further exploration.. 
Current research has established that cancer-related fatigue is a prevalent 
and distressing symptom in TYA cancer patients. It is essential that future research 
now focus on the development of interventions to manage fatigue, in order to limit 
the long-term suffering of this already vulnerable and burdened group of cancer 
patients. Physical activity—including determining its optimal forms and frequency—is 
a key research priority, as is assessing the impact of improving sleep hygiene and 
concurrent symptom control. Research considering parents’ perspectives and 
experiences is also needed given that parental protectiveness may hinder the 
physical activity that could help ameliorate a TYA patient’s fatigue. A deeper of 
understanding of parents’ views and attitudes could facilitate meaningful education of 
parents that, in turn, effectively increases the activity of TYA cancer patients.  
 
Conclusion 
The fatigue experienced by teenagers and young adults with cancer is 
prevalent, persistent, and distressing. It has a negative impact on quality of life and 
social functioning that is particularly problematic at this formative age. The 
magnitude of the problem is established—it is now time to intervene. 
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Table 1. Search Terms 
 
#1 exp fatigue/ 
#2 fatigue* or tire* or exhaust* or lethargy* (title or abstract) 
#3 exp neoplasm/ 
#4 neoplasm* or cancer* or carcinoma* or lymphoma* or leukaemia* or leukemia* (title or abstract) 
#5 1 or 2 
#6 3 or 4 
#7 5 and 6 
#8
a
 limit 7 to ‘adolescent’ or ‘young adult' 
#9 tya* or teenage* or “young adult”* (title or abstract) 
#10 7 and 9 
#11 8 or 10 
a
 Both ‘adolescent’ and ‘young adult’ limiting terms were available in the MEDLINE and CINAHL 
database searches, but only ‘adolescent’ was available for the EMBASE and PsycINFO searches. 
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Table 2. Summary of Key Fatigue Outcome Measures. 
 
Name of measure Description 
Chalder Fatigue Questionnaire
64
 11-item multidimensional fatigue scale developed for use in adult 
epidemiological studies of patients with chronic disease, and to find 
fatigue “cases.”. It is scored using a 4-point verbal rating scale, with a 
case is defined as a score of ≥4 dichotomized bimodal scoring. 
Fatigue Scale-Adolescent
59
 14-item multidimensional scale developed specifically to assess 
cancer-related fatigue in adolescents 13–18 years old. It is scored 
using a 5-point verbal rating scale, and parent and staff proxy 
versions have been developed. 
Functional Assessment in 
Chronic Illness Therapy fatigue 
scale
100
 
Initially developed as a multidimensional measure of fatigue in adult 
oncology patients with anemia, its use has been widened to include 
fatigue assessment in chronic illness. It is a standalone scale within 
the wider FACIT measurement system. It has 13 items, scored using 
a 5-point verbal rating scale. 
Memorial Symptom Assessment 
Scale
17
 
32-item scale developed to assess the frequency, severity, and 
associated distress of 32 common symptoms, (including fatigue) in 
adult cancer patients. Each symptom is measured with 4-point 
(frequency and severity) or 5-point (distress) numerical rating scales. 
It has been modified for use for patients 10–18 (30-item) and 7–12 (8-
item) years old; a number of other revised versions also exist. 
Multidimensional Fatigue Scale 
62
 18-item scale developed to measure fatigue in pediatric cancer 
patients and now used as a generic multidimensional measure in all 
pediatric patient populations. It is a module of the PedsQL 
measurement model, which assesses pediatric quality of life. Versions 
are available for patients 5–7, 8–12, 13–18, and 18–24 years old, with 
associated parent proxy versions. 
Piper Fatigue Scale
101
 Multidimensional fatigue scale developed for use in adult cancer 
patients. A number of versions exist, including the original 40-item 
scale and a revised 22-item scale. Each item is scored with a 0–10 
numerical rating scale. It assesses four domains of fatigue—
behavioral/severity, affective meaning, sensory, and cognitive/mood—
and generates a score for each domain as well as a total score. 
Symptom Distress Scale
102
 11-item scale that measures distress related to symptoms (including 
fatigue) scored using a 5-point verbal rating scale. It was developed 
specifically to identify the concerns of adult patients receiving cancer 
treatment. 
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Table 3. Studies Evaluating Fatigue Prevalence, Grouped by Relationship to Cancer Treatment 
 
Study Aim(s) 
Participants 
(mixed tumors unless 
stated) 
Study design and 
fatigue assessments 
Definition of 
fatigue ‘case’ 
Fatigue prevalence 
(rank compared to other 
symptoms) 
Weight of 
Evidence D 
score 
During treatment      
Ameringer et al. 
2013
57
 
Examine the 
trajectory of 
symptoms across a 
chemotherapy cycle 
 N = 9 
 Mean age: 15.3 years 
 Mean since diagnosis: 
2.6 months 
 Longitudinal 
observational pilot 
 FS-A 
Not described  All participants experienced some 
fatigue at every time point 
Low 
Atay et al. 
2012
73
  
 
Determine symptom 
prevalence 1, 2, and 
3 months after 
diagnosis 
 N = 54 
 61% 13–18 years 
 Longitudinal 
observational 
 MSAS 10-18 
Presence of 
‘lack of energy’ 
in last week on 
MSAS 
 Month 1: 66.7% (5 of 30) 
 Month 2: 75.9% (2 of 30) 
 Month 3: 63% (joint 2 of 30) 
Medium 
Baggott et al. 
2010
71
 
Describe changes in 
symptoms at weekly 
intervals from D1 
 N = 66 
 Mean age: 14.8 years 
 Mean since diagnosis: 
16.3 months 
 Longitudinal 
observational 
 Revised MSAS 10-18 
Presence of 
‘lack of energy’ 
in last week on 
MSAS 
 Week 0: 75.8% (1 of 31) 
 Week 1: 70.5% (2 of 31) 
 Week 2: 57.4% (2 of 31) 
 Significant linear decrease over 
time 
Medium 
Baggott et al. 
2012
65
 
Describe the 
usefulness of eDiary 
to record symptoms 
over a 3-week trial 
 N = 10 
 Mean age: 18.2 years 
 Mean since diagnosis: 
12.2 months 
 Longitudinal 
observational 
 2 questions from FS-A 
in a VAS format 
VAS >30 on 0–
100 scale on at 
least 1 day 
 Reported fatigue-physical and 
fatigue-mental: 100% (1 of 11) 
 % days that VAS >30 on 0–100 
scale, 64% and 62%, respectively 
(1 of 11) 
Low 
Baggott et al. 
2012
70
 
Evaluate symptom 
clusters 
 N = 131 
 Mean age: 14.8 years 
 Median since diagnosis: 
3.3 months 
 Cross-sectional on D0 
of ≥cycle 2 of 
chemotherapy 
 Revised MSAS 10-18 
Presence of 
‘lack of energy’ 
in last week on 
MSAS 
 75.6% (1 of 31) Medium 
Corey et al. 
2008
56
 
Describe the 
relationship between 
support and symptom 
distress 
 N = 72 (ARM 2) 
 Mean age: 14.8 years 
(ARM 2) 
 Mean since diagnosis: 
3.75 years (ARM 1 and 2) 
 Secondary analysis of 
data from 2 studies 
 Symptom Distress 
Scale 
3–5 on 1–5 
Likert scale 
 ARM 2 (recent diagnosis): 42.5% Medium 
Enskar et al. 
2007
66
 
Evaluate distress, 
coping support, and 
care 
 N = 54 
 Mean age: 16.0 years 
 32 were <3 months of 
diagnosis 
 Cross-sectional 
 LSS-A 
Anything other 
than ‘not at all’ / 
‘do not agree at 
all’ on 1–5 VRS 
 For 15 patients on treatment: 93%; 
significantly more than patients off 
treatment (p < 0.05) 
Medium 
Erickson et al. Describe fatigue  N = 20  Longitudinal mixed >0 on 0–10 NRS  Experienced fatigue at some point, Medium 
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2010
23
 patterns during 
month of 
chemotherapy 
 Mean age: 16.1 years 
 Mean since starting 
chemotherapy: 8.71 
weeks 
methods 
 Daily fatigue NRS, 
MFS 
including during ‘days immediately 
following chemotherapy’: 100% 
Erickson et al. 
2011
35
 
Describe relationship 
between fatigue and 
sleep-wake 
disturbances 
 N = 20 
 Mean age: 16.1 years 
 Mean since starting 
chemotherapy: 8.71 
weeks 
 Longitudinal 
observational 
 Weekly MFS from D1 
for 5 weeks 
‘Feeling tired’ 
‘sometimes,’ 
‘often,’ or 
‘almost always’ 
 At some point over study period: 
75% 
Medium 
Hedstrom et al. 
2005
40
 
Investigate 
perceptions of 
distress amongst 
recently-diagnosed 
adolescents 
 N = 56 
 Age (years): 13–15: n = 
35; 16–19: n = 21 
 Cross-sectional, 
mixed methods 
 Fatigue assessed as 
an aspect of distress 
using Likert scale 
3–5 on 0–5 
Likert scale 
 62% (4 of 20) Medium 
Mandrell et al. 
2011
47
 
Calculate the revised 
FS-A score that 
defines a fatigue 
‘case’ meriting 
clinical intervention 
 N = 138 
 Mean age: 14.83–16.27 
years across all studies 
 Analysis of data from 
9 studies 
 FS-A and FS-P 
>31 on scale of 
13–65 
 ALL: 15%; 7–14%/26–33% (ALL 
off/on DXM) 
 Solid tumor or AML: 10% (D1), 
28% (D2), 50% (D3–4) 
 Mixed diagnoses: 36% (D1); 56% 
(final day); 54% (1 week after end) 
High 
Miller et al. 
2011
72
 
Describe prevalence, 
frequency, severity, 
and distress of 
multiple symptoms 
 N = 39 
 Mean age: 13.5 years 
 Longitudinal 
observational 
 MSAS 10-18 daily for 
5 days evaluating 
symptoms from ‘past 
day’ 
Presence of 
‘lack of energy’ 
in last week on 
MSAS 
 49.6% (2 of 31) Medium 
Walker et al. 
2010
68
 
Describe symptoms 
before (T1) and 1 
week after (T2) 
chemotherapy 
 N = 51 
 Mean age: 14.2 years 
 Mean since diagnosis: 6 
months 
 Longitudinal 
observational in 2 
centers 
 MSAS 7–12 
Presence of 
‘tiredness’ in last 
week on MSAS 
7–12 
 T1: 54.3% (1 of 9) 
 T2: 67.4% (1 of 9) 
Medium 
Williams et al. 
2012
69
 
Calibrate the 
Therapy-Related 
Symptom Checklist-
Children 
 N = 163 
 Subgroup of 385 
participants in age range 
12–17 years  
 Cross-sectional 
 TRSC-C 
Severity of 
‘feeling sluggish’ 
of more than 0 
on 0–4 Likert 
 81% (1 of 31) Medium 
After treatment      
Adams et al. 
2004
52
 
Evaluate 
cardiovascular 
function after 
 N = 48 HD survivors 
 Median age at diagnosis: 
14.2 years 
 Cross-sectional 
 General Health 
Survey (unvalidated 
≥1 on 0–4 Likert 
scale of fatigue 
severity 
 67% Medium 
39 
 
mediastinal RT  Median since diagnosis: 
14.3 years 
tool) 
Aksnes et al. 
2007
54
 
Examine fatigue, 
mental distress, and 
QOL in EBT 
survivors compared 
to matched controls 
 N = 57 EBT survivors 
 Mean age at diagnosis 
across subgroups: 16–25 
years 
 Mean since diagnosis: 9–
14 years 
 Case-control (non-
contemporaneous 
controls HD, TC, 
NORMS) 
 CFQ 
Sum of ≥4 using 
dichotomized (0, 
0, 1, 1) 4-point 
Likert scale 
 EBT survivors: 14% 
 HD survivors: 21% 
 TC survivors: 16% 
 NORMS: 10%; p = 0.3 EBT vs. 
NORMS 
Medium 
Enskar et al. 
2007
66
 
Evaluate distress, 
coping support, and 
care 
 N = 54 
 Mean age: 16.0 years 
 32 were <3 months of 
diagnosis 
 Cross-sectional 
 LSS-A 
Anything other 
than ‘not at all’ 
on 1–5 VRS 
 For 39 patients after treatment: 
67%, less than on treatment (p < 
0.05) 
Medium 
Hamre et al. 
2013
32
 
Determine 
prevalence of chronic 
fatigue in 
leukemia/lymphoma 
survivors 
 N = 92 (subgroup of 290); 
all HD 
 Mean age diagnosis: 14.6 
years 
 Mean age at survey: 35.0 
years 
 Cross-sectional 
 CFQ 
Sum of ≥4 using 
dichotomized (0, 
0, 1, 1) 4-point 
Likert scale 
 35% vs. 8% in control group (note 
control group age = 19–50 years) 
 Adjusted odds ratio of fatigue in 
HD vs. control: 5.9 
Low 
Mulrooney et al. 
2008
50
 
Describe prevalence 
and risk factors for 
fatigue and sleep 
disturbance 
 N = 631 (subgroup of 
1897) 
 Diagnosed age: 15–21 
years 
 >5 years from diagnosis 
 26-center cohort study 
 FACIT-fatigue 
Score below 
10th percentile 
for sibling cohort 
 8.6% Medium 
Mixed during and after treatment     
Collins et al. 
2000
17
 
Determine symptom 
prevalence, 
characteristics, and 
distress 
 N = 160 
 70 had chemotherapy 
within last 2–4 weeks, 58 
>4 months ago 
 Mean age: 14.0 years 
 Cross-sectional 
 MSAS 10–18 
Presence of 
‘lack of energy’ 
in last week on 
MSAS 
 Overall: 49.7% (1 of 30) 
 CNS tumor: 66.7% (1 of 30) 
 Lymphoma: 50% (1 of 30) 
 Leukemia: 43.8% (2 of 30) 
 Solid tumor: 53.7% (3 of 30) 
Medium 
Corey et al. 
2008
56
 
Describe relationship 
between distress and 
three sources of 
support 
 N = 127 (ARM 1) 
 Mean age: 16.4 years 
(ARM 1) 
 Mean since diagnosis: 
3.75 years (ARM 1 and 2) 
 Secondary analysis of 
data from 2 studies 
 Symptom Distress 
Scale 
3–5 on 1–5 
Likert scale 
 ARM 1 (mixed population): 31.4% 
 1-year increase in age increased 
odds of fatigue by 1.23–1.25 
High 
Enskar et al. 
1997
67
 
Evaluate 
adolescents’ 
experience of areas 
of life affected by the 
 N = 10 
 Age 13–16 years at 
diagnosis n = 8 
 Age at interview: 15–20 
 Cross-sectional 
observational 
 5-point NRS (non-
validated 
≥2 on 1–5 NRS  100% Medium 
40 
 
ALL, acute lymphatic leukemia; AML, acute myeloid leukemia; ARM 1, Adolescent Resilience Model study 1; ARM 2, Adolescent Resilience Model study 2; 
CFQ, Chalder Fatigue Questionnaire; CNS, central nervous system; D1, D2, etc., day 1, day 2, etc.; DXM, dexamethasone; EBT, extremity bone tumor; 
FACIT-fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue Scale; FS-A, Fatigue Scale-Adolescent; FS-P, Fatigue Scale-Parent; HD, Hodgkin 
disease; LSS-A, Life Situation Scale for Adolescents; MFS, Multidimensional Fatigue Scale; MSAS (7–12, 10–18), Memorial Symptom Assessment Scale (for 
7–12 and 10-18 age range); NORMS, healthy controls; NRS, Numerical Rating Scale; QOL, quality of life; RT, radiotherapy; T1, T2, etc., time point 1, time 
point 2, etc.; TC, testicular cancer; TRSC-C, Therapy-Related Symptom Checklist-Children; VAS, Visual Analogue Scale; VRS, Verbal Rating Scale. 
  
disease years questionnaire) 
Ream et al. 
2006
18
 
Investigate impact of 
fatigue on 
adolescents 
 N = 22 
 Age: 13–20 years 
 Longitudinal, mixed 
methods 
 Daily diary entry and 
completion of fatigue 
NRS 
Mention of 
fatigue in diary 
entries 
 Mentioned fatigue during 
treatment: 32; 30% in early 
remission (1–2 years after 
treatment), 10% in late remission 
(>5 years) 
Medium 
Yeh et al. 
2008
33
, 2009
34
 
Assess symptoms in 
older Taiwanese 
children 
 N = 144 
 Mean age: 14.2 years 
 For 108 on treatment, 
mean since diagnosis: 
21.2 months 
 Cross-sectional 
observational 
 MSAS 10–18 
Presence of 
‘lack of energy’ 
in last week on 
MSAS 
 52% (1 of 30) 
 On/off treatment: 52.8%, 50.0% 
 Leukemia: 57.3% 
 Lymphoma: 46.2% 
 Solid tumor: 46.5% 
Medium 
41 
 
Table 4. Controlled Studies Evaluating Fatigue Severity 
 
Study Aim(s) 
Participants 
(mixed tumors unless stated) 
Study design and fatigue 
assessments 
Fatigue severity 
Weight of 
Evidence D 
score 
Aksnes et al. 
2007
54
 
Examine fatigue, 
mental distress, and 
QOL in EBT 
survivors compared 
to matched controls 
 N = 57 EBT survivors 
 Mean age at diagnosis within 
different cancer type subgroups: 
16–25 years 
 Mean since diagnosis: 9–14 years 
 Case-control (non-
contemporaneous age- 
and gender-matched 
controls HD, TC, NORMS) 
 CFQ 
 Mean total fatigue: 
 EBT survivors: 13.2 
 HD survivors: 13.4 
 TC survivors: 13.4 
 NORMS: 11.8 
 EBT survivors had significantly more fatigue 
than NORMS (p = 0.003), but not more than 
other survivor groups 
Medium 
Daniel et al. 
2013
30
 
Compare 
adolescent and 
parent reports of 
fatigue in patients 
with and without 
cancer 
 N = 102 with cancer on treatment 
 Mean age: 15.75 years 
 Mean since diagnosis: 20.4 
months 
 N = 97 controls; mean age: 15.55 
years 
 Cross-sectional 
observational 
(contemporaneous 
controls) 
 MFS 
 MFS score in cancer and control groups, 
respectively: 58.54 and 71.72 (p < 0.001) 
 Total fatigue, general fatigue, and sleep/rest 
fatigue worse, but not cognitive fatigue 
High 
Smith et al. 
2013
51
 
Examine HRQOL of 
AYA patients and 
associated health-
related 
characteristics 
 N = 159 
 Age: 15–25 years 
 Subgroup of large AYA HOPE 
study with 523 cancer patients 
aged 15–39 at diagnosis 
 Since diagnosis at survey: 6–14 
months 
 80% not on treatment 
 Cross-sectional 
observational (compared 
to age-range matched 
population norms) 
 MFS 
 Mean MFS scores: 
 Ages 18–25: 61.3, significantly worse than 
reference healthy population score of 71.0 
(p = 0.001) 
 Ages 15–17: 59.8, not significantly different 
from ages 18–25 (no reference data for this 
age range) 
Medium 
AYA, adolescent and young adult; AYA HOPE, Adolescent & Young Adult Health Outcomes & Patient Experience study; CFQ, Chalder Fatigue 
Questionnaire; EBT, extremity bone tumor; HD, Hodgkin disease; HRQOL, health-related quality of life; MFS, Multidimensional Fatigue Scale; NORMS, 
healthy controls; QOL, quality of life; TC, testicular cancer 
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Table 5. Studies with Fatigue Interventions. 
 
Study Aim(s) 
Participants 
(mixed tumors 
unless stated) 
Study design and intervention Fatigue assessments Results 
Weight of 
Evidence D 
score 
Atkinson et 
al. 
2012
86
 
Determine the 
impact of a 
structured exercise 
intervention 
 N = 55 
 Age: 15–25 
years 
 Uncontrolled trial 
 2–3 sessions/week individual 
structured exercise in a 
hospital/private gymnasium with 
an exercise physiologist over 10 
weeks 
 Assessed pre- and post-
intervention 
 Revised PFS, Ferrans and 
Powers QLI, measures of 
functional fitness 
 Improvement in fatigue (p ≤ 
0.0001), as well as QOL 
and functional 
assessments 
 PFS scores decreased by 
32% 
Medium 
Hinds et al. 
2000
43
 
Evaluate effects of 
an educational 
intervention 
designed to 
facilitate self-care 
coping 
 N = 78 
 Mean age: 16.0 
years 
 Two-center randomized controlled 
trial 
 40-minute intervention between 
T1 (1–12 days after diagnosis) 
and T2 (5–7 weeks after): 
information on self-care coping, 
video with strategies, and 
rehearsal of strategies 
 Control had equal time to discuss 
any topic 
 Assessed at T1, T2, 3 
months, and 6 months 
after diagnosis 
 Six outcome measures, 
including SDS (includes 5-
point fatigue severity VRS) 
 No difference in SDS score 
between groups at any 
time point 
 Fatigue 1 of 4 most 
distressing symptoms at 
every time point 
Low 
Hinds et al. 
2007
74
 
Evaluate the 
feasibility of using 
an enhanced 
physical activity 
intervention 
 N = 11 
 Subgroup age: 
13–18 years 
 Two-center pilot randomized 
controlled trial 
 Pedaling a stationary bicycle 
exerciser for 30 minutes twice 
daily for 2–4 days of 
hospitalization with equipment 
brought to hospital room 
 Control spent equal time with 
researcher 
 Assessed daily on days 1, 
2, and 3 
 Patient, parent, and staff 
fatigue reports (FS-C, -A, -
P, -S), wrist actigraphy, 
parent sleep diary, 
hemoglobin 
 No difference between 
groups 
Medium 
Keats et al. 
2008
79
 
Assess feasibility of 
a physical activity 
intervention 
 N = 10 
 Age: 14–18 
years 
 Mean since 
diagnosis: 62.5 
months 
 Uncontrolled feasibility study 
 Weekly 90 minutes of group 
education and training for 8 weeks 
in gymnasium, then variety of 
non-competitive activities over 16 
weeks 
 Assessed at baseline, 
week 8, week 16, 3 
months, and 1 year 
 PedsQL, MFS, Leisure 
Score Index, FitnessGram 
(a physical fitness test) 
 Improvement in fatigue 
between baseline and 3 
months (p = 0.01), but 
post-intervention benefits 
not sustained at 3 months 
and 1 year 
Medium 
Rosenhagen 
et al. 
Investigate 
feasibility and 
 N = 13 
 Mean age: 15.3 
 Uncontrolled feasibility study 
(control group gave acceptability 
 Assessed on days 1 and 
14 and on discharge after 
 Non-significant trend for 
fatigue improvement pre- 
Low 
43 
 
2011
87
 acceptability of 
sports therapy 
years data only) 
 Individualized exercise using 
ergometer in hospital room during 
isolation phase of SCT 
SCT 
 QOL self-assessment, 
MFS 
and post-intervention 
FS-A, Fatigue Scale-Adolescent; FS-C, Fatigue Scale-Child; FS-P, Fatigue Scale-Parent; FS-S, Fatigue Scale-Staff; MFS, Multidimensional Fatigue Scale; 
PedsQL, Pediatric Quality of Life Inventory; PFS, Piper Fatigue Scale; QLI, quality of life index; QOL, quality of life; SDS, Symptom Distress Scale; SCT, stem 
cell transplant; T1, T2, etc., time point 1, time point 2, etc.; VRS, Verbal Rating Scale 
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Figure Legend 
 
Figure 1. PRISMA flowchart of included articles 
Note: Although four pairs of articles and two groups of three articles were 
publications describing different aspects of the same study’s data set, 
because of the distinct areas of focus, the 60 articles have been viewed as 60 
separate studies. 
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-
Analyses 
 
 
 
 
